Table 2. .
Univariable and Multivariable Hazard Ratios for Incident Clinical Events or Death From Any Cause Among the 148 PWH and 4-Class Drug-Resistant Virus
| Univariable Analysis | Multivariable Analysisa | ||||
|---|---|---|---|---|---|
| Covariate | Category | Hazard Ratio (95% CI) | P Value | Adjusted Hazard Ratio (95% CI) | P Value |
| Age | Per 1 y older | 1.036 (0.993–1.080) | .102 | 1.022 (0.972–1.073) | .397 |
| Gender | Female vs male | 0.546 (0.210–1.418) | .194 | 0.773 (0.264–2.262) | .639 |
| HCVAb | Positive vs negative | 1.227 (0.546–2.758) | .621 | Not included | - |
| HBsAg | Positive vs negative | 2.856 (0.377–21.634) | .310 | Not included | - |
| Years since HIV diagnosis | Per 1 y longer | 1.003 (0.906–1.024) | .230 | Not included | - |
| Years of ART | Per 1 y longer | 0.967 (0.898–1.041) | .369 | Not included | - |
| Pre-ART HIV-RNA | Per 1 log10 copies/mL higher | 0.628 (0.181–2.178) | .464 | Not included | - |
| Nadir CD4+ cell count | Per 100 cells/µL higher | 0.531 (0.346–0.816) | .004 | 0.756 (0.487–1.173) | .212 |
| Previous AIDS events | ≥1 vs none | 2.313 (1.141–4.688) | .020 | Not included | - |
| Previous non-AIDS event | ≥1 vs none | 2.724 (1.327–5.593) | .006 | Not included | - |
| Previous AIDS or non-AIDS event | ≥1 vs none | 3.644 (1.760–7.547) | 0.0005 | 2.674 (1.067–6.667) | .036 |
| BL plasma HIV-1 RNA | ≥50 vs <50 copies/mL | 2.209 (0.300–16.250) | .436 | Not included | - |
| BL plasma HIV-1 RNA | Per 1 log10 copies/mL higher | 1.299 (0.967–1.745) | .083 | 0.992 (0.615–1.600) | .973 |
| BL CD4+ cell count | Per 100 cells/µL higher | 0.802 (0.687–0.936) | .005 | Not included | - |
| BL CD8+ cell count | Per 100 cells/µL higher | 1.031 (0.965–1.101) | .363 | Not included | - |
| BL CD4+/CD8+ ratio | Per 0.1 unit higher | 0.729 (0.602–0.885) | .001 | 0.816 (0.654–1.019) | .072 |
| Burden of resistance (RGSS score) | ≤5.5 vs >5.5b | 1.630 (0.830–3.204) | .176 | Not included | - |
| Burden of resistance (RGSS score) | Per 1 point higher | 0.962 (0.882–1.049) | .179 | 1.051 (0.936–1.180) | .400 |
Abbreviations: 4DR, 4-class drug-resistant; ART, antiretroviral therapy; BL, baseline (date with the first evidence of a 4DR virus); RGSS, Residual Genotypic Susceptibility Score.
aCovariates with univariable P value <.20 were included in the final multivariable model.
bMedian value.